BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 28714517)

  • 1. Overexpression of the erythropoietin receptor in RAMA 37 breast cancer cells alters cell growth and sensitivity to tamoxifen.
    Ilkovičová L; Trošt N; Szentpéteriová E; Solár P; Komel R; Debeljak N
    Int J Oncol; 2017 Aug; 51(2):737-746. PubMed ID: 28714517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.
    Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR
    Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation.
    Reinbothe S; Larsson AM; Vaapil M; Wigerup C; Sun J; Jögi A; Neumann D; Rönnstrand L; Påhlman S
    Biochem Biophys Res Commun; 2014 Feb; 445(1):163-9. PubMed ID: 24502950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer.
    Larsson AM; Jirström K; Fredlund E; Nilsson S; Rydén L; Landberg G; Påhlman S
    Clin Cancer Res; 2009 Sep; 15(17):5552-9. PubMed ID: 19706814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-stimulation with stem cell factor and erythropoietin enhances migration of c-Kit expressing cervical cancer cells through the sustained activation of ERK1/2.
    Aguilar C; Aguilar C; Lopez-Marure R; Jiménez-Sánchez A; Rocha-Zavaleta L
    Mol Med Rep; 2014 May; 9(5):1895-902. PubMed ID: 24626629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between erythropoietin receptor(s) and estrogen and progesterone receptor expression in different breast cancer cell lines.
    Trošt N; Hevir N; Rižner TL; Debeljak N
    Int J Mol Med; 2013 Mar; 31(3):717-25. PubMed ID: 23314808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin receptor induces a paclitaxel resistance phenotype in mammary adenocarcinoma cells.
    Zsóková E; Ilkovičová L; Kimáková P; Fecková B; Solár P
    Oncol Rep; 2019 Sep; 42(3):1149-1160. PubMed ID: 31322257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No erythropoietin-induced growth is observed in non-small cell lung cancer cells.
    Frille A; Leithner K; Olschewski A; Olschewski H; Wohlkönig C; Hrzenjak A
    Int J Oncol; 2018 Feb; 52(2):518-526. PubMed ID: 29345289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs.
    Gewirtz DA; Di X; Walker TD; Sawyer ST
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2232-8. PubMed ID: 16609039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin receptor contributes to melanoma cell survival in vivo.
    Kumar SM; Zhang G; Bastian BC; Arcasoy MO; Karande P; Pushparajan A; Acs G; Xu X
    Oncogene; 2012 Mar; 31(13):1649-60. PubMed ID: 21860424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin promotes hair shaft growth in cultured human hair follicles and modulates hair growth in mice.
    Kang BM; Shin SH; Kwack MH; Shin H; Oh JW; Kim J; Moon C; Moon C; Kim JC; Kim MK; Sung YK
    J Dermatol Sci; 2010 Aug; 59(2):86-90. PubMed ID: 20554434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human rhabdomyosarcoma cells express functional erythropoietin receptor: Potential therapeutic implications.
    Poniewierska-Baran A; Suszynska M; Sun W; Abdelbaset-Ismail A; Schneider G; Barr FG; Ratajczak MZ
    Int J Oncol; 2015 Nov; 47(5):1989-97. PubMed ID: 26412593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.
    Acs G; Zhang PJ; McGrath CM; Acs P; McBroom J; Mohyeldin A; Liu S; Lu H; Verma A
    Am J Pathol; 2003 Jun; 162(6):1789-806. PubMed ID: 12759237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells.
    Kumar SM; Yu H; Fong D; Acs G; Xu X
    Melanoma Res; 2006 Aug; 16(4):275-83. PubMed ID: 16845323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioblastoma multiforme cells: expression of erythropoietin receptor and response to erythropoietin.
    Yin D; Kawabata H; Tcherniamtchouk O; Huynh T; Black KL; Koeffler HP
    Int J Oncol; 2007 Nov; 31(5):1193-8. PubMed ID: 17912447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.